STLNW (Starling Oncology) Issuance of Debt: $0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STLNW Starling Oncology Inc STLNW
61 GF Score
Price $0.06
! 4 Warning Signs
View Full Analysis

What is Starling Oncology Issuance of Debt?

Starling Oncology STLNW 61 Issuance of Debt is $0.00 Mil as of Mar. 2026. GuruFocus rates STLNW with a GF Score™ of 61/100. The stock has 4 warning signs investors should review.

Starling Oncology's Issuance of Debt for the three months ended in Mar. 2026 was $0.00 Mil.

Starling Oncology's Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Starling Oncology Issuance of Debt Related Terms

Starling Oncology Issuance of Debt Historical Data

* Premium members only.

The historical data trend for Starling Oncology's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Starling Oncology Issuance of Debt Chart

Starling Oncology Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Issuance of Debt
Get a 7-Day Free Trial 0.00 110.00 0.00 0.00 0.00

Starling Oncology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STLNW
61GF Score
Starling Oncology Inc STLNW
Issuance of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Starling Oncology Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of $0.00 Mil mean?
Starling Oncology (STLNW) has a Issuance of Debt of $0.00 Mil as of Mar. 2026. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Starling Oncology and its competitors.
Is Starling Oncology's Issuance of Debt too high?
Starling Oncology's current Issuance of Debt is $0.00 Mil. Overall, Starling Oncology has a GF Score™ of 61/100, reflecting its overall financial health beyond just this single metric.
How does Starling Oncology's Issuance of Debt compare to SRTA and CCRN?
Starling Oncology's Issuance of Debt of $0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Healthcare Providers & Services company?
A good Issuance of Debt depends on the Healthcare Providers & Services industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Starling Oncology and its competitors. Starling Oncology's current Issuance of Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Starling Oncology stock overvalued right now?
Starling Oncology (STLNW) has a current Issuance of Debt of $0.00 Mil. The current Issuance of Debt is $0.00 Mil. Starling Oncology's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For Starling Oncology (STLNW), the current Issuance of Debt is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Starling Oncology Business Description

Other Exchanges TOI:USA
Address 18000 Studebaker Road, Suite 800, Cerritos, CA, USA, 90703
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
61GF Score

Get the complete analysis for STLNW

Issuance of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.06
Price